Merck: revises forecasts for 2023
(CercleFinance.com) - Merck announces that its sales reached $16.
96bn in Q3, up 7% y-o-y (+9% cer).
Its adjusted net income came to $5.42bn, up 15% (+22% cer), giving adjusted EPS of $2.13, up 15% (+22% cer).
Against this backdrop, the pharma group has adjusted its FY 2023 guidance, now targeting sales of $59.7bn to $60.2bn (vs. $58.6bn to $59.6bn previously).
However, it now expects 2023 adjusted EPS between $1.33 and $1.38, well below its previous forecast range of $2.95 to $3.05, in particular due to a sharp rise in adjusted capex (from $100m to $200m) and pre-tax expenses of $5.5bn, or $1.70 per share, relating to its collaboration agreement with Daiichi Sankyo.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
96bn in Q3, up 7% y-o-y (+9% cer).
Its adjusted net income came to $5.42bn, up 15% (+22% cer), giving adjusted EPS of $2.13, up 15% (+22% cer).
Against this backdrop, the pharma group has adjusted its FY 2023 guidance, now targeting sales of $59.7bn to $60.2bn (vs. $58.6bn to $59.6bn previously).
However, it now expects 2023 adjusted EPS between $1.33 and $1.38, well below its previous forecast range of $2.95 to $3.05, in particular due to a sharp rise in adjusted capex (from $100m to $200m) and pre-tax expenses of $5.5bn, or $1.70 per share, relating to its collaboration agreement with Daiichi Sankyo.
Copyright (c) 2023 CercleFinance.com. All rights reserved.